3d human heart  medical anatomy

Understanding Lipoprotein(a)- Novel Therapeutics to Reduce Lp(a) Levels and Improve Cardiovascular Outcomes

http://academiccme.com/wp-content/uploads/2018/10/iStock-1035980904-1-wpcf_400x400.jpg

Course Information

Therapautic Area: Cardiology
Format(s): Post Conference Review and Analysis
Credit(s): 1.0 AMA PRA Category 1 Credit™; 1.0 CNE contact hour
Activity Dates: October 29, 2018 - October 28, 2019

 

Program Overview

This CME/CNE program will highlight content presented at the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany. The three expert faculty, led by Dr. Patrick M. Moriarty, will assess the role of lipoprotein(a)- novel therapeutics in reducing Lp(a) levels and improving cardiovascular outcomes. A state of the science of lipoprotein(a), including the mechanism of action, subtypes and prevalence, will be provided before delving into recent clinical trial data for the management of atherosclerotic disease. Data regarding Lp(a) from the ASTROMER, JUPITER, FOURIER and ODYSSEY trials, among others, will be presented and clinical relevance debated in an interactive panel discussion. Recent guidelines as well as strategies for incorporating Lp(a) reduction therapies to reduce risk and improve cardiovascular outcomes will be relayed. At the conclusion of this CME/CNE activity learners will have a better understanding of lipoprotein(a) and its clinical considerations when treating patients with cardiovascular disease.

Target Audience

Cardiologists, primary care physicians, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with atherosclerosis

Learning Objectives

  1. Identify the role of atherogenic states, such as elevated apoliprotein B and lipoprotein(a), as a risk factor for coronary artery disease
  2. Analyze clinical trial data of novel therapeutics for the management of atherosclerotic disease in high-risk patients, as presented at ESC 2018
  3. Develop strategies to incorporate Lp(a) reduction therapies to reduce risk and improve cardiovascular outcomes, incorporating the appropriate healthcare team members

Faculty

Moriarty (1)

Patrick M. Moriarty, MD (Course Chair)
Director, Atherosclerosis/Lipoprotein-Apheresis Center and the Division of Clinical Pharmacology
Professor of Medicine
University of Kansas Medical Center
Kansas City, Kansas

 

 

Cannon Headshot (1)Christopher P. Cannon, MD
Director, Education, Cardiovascular Medicine Innovation
Cardiovascular Division, Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

 

 

Underberg #6 (1)James A. Underberg, MD, MS
Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
President, National Lipid Association
New York, New York

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Faculty Relationship Identified With:
Patrick M. Moriarty, MD Consultant/Advisor: Aegerion Pharmaceuticals Inc; Amgen Inc; Duke; Eliaz Therapeutics; Esperion; Gemphire Therapeutics; Kaneka Corporation; Kastle Therapeutics; Novartis AG; Regeneron; Sanofi; Stage 2 InnovationsSpeaker’s Bureau: Amarin Corporation; Ambry Genetics Corp.; Amgen Inc; Regeneron; REGENXBIO Inc.; SanofiResearch/Grant Support: Akcea Therapeutics; Amgen Inc; FH Foundation; Gemphire Therapeutics; Ionis Pharmaceuticals; Kaneka Corporation; Kowa Company, Ltd.; Novartis AG; Pfizer Inc.; Regeneron; Sanofi; Stage 2 Innovations; Zydus Pharmaceuticals
Christopher P. Cannon, MD Consultant/Advisor: Alnylam Pharmaceuticals, Inc.; Amarin Corporation; Amgen Inc; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Janssen Global Services, LLC; Kowa Company, Ltd.; Merck & Co.; Pfizer Inc.; Regeneron; SanofiResearch/Grant Support: Amgen Inc; Boehringer Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo Company, Limited; Janssen Global Services, LLC; Merck & Co.
 James A. Underberg, MD, MS  Consultant/Advisor: Akcea Therapeutics; Alexion Pharmaceuticals; Amarin Corporation; Amgen Inc; Invitae Corporation; Regeneron; SanofiSpeaker’s Bureau: Akcea Therapeutics; Alexion Pharmaceuticals; Amarin Corporation; Amgen Inc; Regeneron; SanofiResearch/Grant Support: Aegerion Pharmaceuticals Inc; Pfizer Inc.

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission (ANCC) on Accreditation. AcademicCME’s ANCC provider number is P0491.

Financial Support

This activity has been supported by an independent educational grant from Amgen Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions.
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
8. 60 minutes of participation = 1 CNE contact hour

CE Inquiries/Special Needs

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

BUTTON


Provided by: AcademicCME-web